Month: April 2024

Falcon Oil & Gas Ltd.(“Falcon” or “Company”) Shenandoah South-1H well IP90 Day Flow Rates of 2.9 MMcf/d (normalised to 5.8 MMcf/d) 26 April 2024 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce that the Shenandoah South 1H (SS-1H) well in EP117 achieved above commercial IP90 flow rate of 2.9 MMcf/d (normalised to 5.8 MMcf/d over 1,000 metres). Highlights are as follows:The SS-1H well in EP117 achieved an average 90-day initial production (IP90) flow rate of 2.9 million cubic feet per day (MMcf/d) over the 1,644-foot (501 metres), 10 stage stimulated length within the Amungee Member B-Shale, normalised to 5.8 MMcf/d over 3,281-feet (1,000 metres). On completion of the IP90 flow test, the well was delivering 2.7 MMcf/d, normalized to 5.4 MMcf/d over 3,281-feet (1,000 metres) at a pressure of 518 psi prior to...

The shares in Kitron ASA will be traded ex dividend NOK 0.75 as from today, 26.04.2024. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Lassila & Tikanoja plc Stock exchange release 26 April 2024 at 8:00 a.m. Lassila & Tikanoja plc: Interim Report 1 January–31 March 2024 STABLE RESULT IN THE FINNISH DIVISIONS – FACILITY SERVICES SWEDEN DID NOT MEET EXPECTATIONS Unless otherwise mentioned, the figures in brackets refer to the corresponding period in the previous year.Net sales for the first quarter were EUR 185.0 million (192.7). Net sales decreased by 4.0%. The decline in net sales was due to the weak economic environment. Adjusted operating profit was EUR 0.0 million (1.4) and operating profit was EUR -1.7 million (1.4). Earnings per share were EUR -0.02 (0.03). Net cash flow from operating activities after investments was EUR -9.4 million (19.2) and net cash flow from operating activities after investments per share was EUR -0.25 (0.50). Net cash flow was...

The retail turnover (including VAT) of Apranga Group reached EUR 72.3 million in Q1 2024 and was by 11.0% higher than in 2023. The unaudited consolidated profit before income tax of Apranga Group amounted to EUR 1.3 million in 3 months 2024, while Apranga Group had the profit of EUR 1.4 million in the same period of 2023. EBITDA of Apranga Group reached EUR 6.4 million in 3 months 2024, while it amounted to EUR 6.2 million in corresponding period of 2023. The unaudited interim consolidated financial statements of Apranga Group for 3 months 2024, as well as managers’ confirmation letter are ready for acquaintance in the attachments. The interim information is also available at: http://aprangagroup.lt/en/investors. Rimantas PerveneckasApranga Group General Manager+370 5 2390801      AttachmentFA2024Q1 EN

IMCD_logoLogo IMCDRotterdam, The Netherlands (26 April 2024) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTSGross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023) Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis) Free cash flow of EUR 106 million (first three months of 2023: EUR 147 million) Cash earnings per share decline of 19% to EUR 1.41 (first three months of 2023: EUR 1.74) Successful completion of six acquisitions: Valuetree and CJ Shah in India, Joli Foods in Colombia, RBD in China, Euro Chemo-Pharma/Biofresh in Malaysia and Gova in the BeneluxValerie Diele-Braun, CEO: “In a volatile...

Press Release April 26, 2024 Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million First quarter 20241Signify’s installed base of connected light points increased from 124 million in Q4 23 to 126 million in Q1 24 Achieved reasonable assurance on full Brighter Lives, Better World 2025 program, including scope 3 emissions Sales of EUR 1,468 million; nominal sales decline of -12.5% and CSG of -10.1% LED-based sales represented 87% of total sales (Q1 23: 82%) Adj. EBITA margin of 8.3% (Q1 23: 8.9%) Net income of EUR 44 million (Q1 23: EUR 28 million) Free cash flow of EUR 80 million (Q1 23: EUR 51 million)Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s first quarter 2024 results. “In the...

Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through the application of science, today publishes its results for the quarter ending 31 March 2024. Key highlights first quarter of 2024Organic growth core activities:Sales: volume/mix +1.7%, price -4.5% Adjusted EBITDA: +0.7% Adjusted EBITDA margin 13.8% (+ 50bps versus last year)Sales € 344.3 million; an organic decrease of -3.4% Adjusted EBITDA € 47.2 million; an organic decrease of -1.2% Positive Free Cash Flow € 7.5 million Double digit growth in sales and Adjusted EBITDA in Health & Nutrition TotalEnergies Corbion joint venture: sales € 31.6 million; an organic growth of 24.3% Divestment of non-core US Emulsifier business completed on April 1st Share buyback program of € 20.0 million and special cash dividend of € 0.10 per share Confirmation...

Hexatronic Group AB (publ)Interim report January – March 2024 Continued strong operating cash flow and contribution from new focus areas First quarter (January 1 – March 31, 2024)Net sales decreased by 16 percent to MSEK 1,782 (2,115). Sales decreased organically by 27 percent. EBITA decreased by 54 percent to MSEK 168 (365), corresponding to an EBITA margin of 9.4 percent (17.2). Operating profit (EBIT) decreased by 59 percent to MSEK 138 (340), corresponding to an operating margin of 7.7 percent (16.1). Net profit decreased by 73 percent to MSEK 61 (224). Earnings per share after dilution amounted to SEK 0.31 (1.09). Leverage ratio (net debt/EBITDA (pro forma), R12) amounted to 2.0x compared to 1.7x as of December 31, 2023. Cash flow from operating activities amounted to MSEK 270 (28).Significant events during the quarterThe Board...

Ad hoc announcement pursuant to Art. 53 LRIdorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. A CHMP positive opinion is one of the final steps before marketing authorization can be granted by the European Commission – a final decision is expected in approximately two months.Allschwil, Switzerland – April 26, 2024Idorsia Ltd (SIX: IDIA) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of JERAYGO™ (aprocitentan) for the treatment of resistant...